Author

Wen-Chi Chou

Observed name: W.-C. Chou

Institution: Bristol-Myers Squibb (United States)

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5015022002

S216: Clinical Activity of Cc-99282, a Cereblon E3 Ligase Modulator (celmod) Agent, in Patients (pts) With Relapsed/refractory Non-hodgkin Lymphoma (r/r Nhl) – Results From a Phase 1, Open-label Study

2022 · J.-M. Michot, J. C. Chavez, et al. · HemaSphere · 4

Abstract CT079: Pharmacodynamic (PD) and exploratory biomarker (BM) analysis of the PRMT5 inhibitor BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)

2025 · Jordi Rodón, Tyler Simpson, et al. · Cancer Research · 1

Abstract 502: Comparison of MTAP loss by immunohistochemistry (IHC) and MTAP homozygous deletion by next-generation sequencing (NGS) and DNA fluorescence in-situ hybridization (FISH).

2026 · Lisa Huang, Lauren Giampapa, et al. · Cancer Research

Genomic characteristics, clinical profiling, and outcomes of advanced pancreatic ductal adenocarcinoma (PDAC) with MTAP -deletion ( MTAP -del): Analyses from a multimodal real-world dataset.

2026 · Micaela Tatman, Daiane Hemerich Brennan, et al. · Journal of Clinical Oncology

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

2022 · Soraya Carrancio, Wen-Chi Chou, et al. · Blood

Works count: 5

Citation count: 5

H-index: 1

I10-index: